Asset Details
Do you wish to reserve the book?
Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome : a systematic review and meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome : a systematic review and meta-analysis
Do you wish to request the book?
Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome : a systematic review and meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome : a systematic review and meta-analysis
2020
Overview
Treatments that target alterations in gut microbiota may be beneficial for patients with irritable
bowel syndrome (IBS). A systematic review and meta-analysis was conducted of randomised clinical trials (RCTs)
evaluating the efficacy and safety of probiotics, prebiotics and synbiotics. Factors considered in the analysis
included global IBS symptoms and/or abdominal pain, secondary symptoms and the frequency of adverse events.
A total of 33 RCTs involving 4,321 patients were identified. Overall, probiotics significantly improved global IBS
symptoms compared to placebos (standardised mean difference = −0.32, 95% confidence interval: −0.48 to −0.15;
P <0.001), with significant heterogeneity between studies (I2 = 72%; P <0.001). This remained apparent in both
single- and multi-strain probiotic interventions as well as synbiotic formulations. However, evidence regarding
prebiotics was scarce. There were no significant inter-group differences in terms of the frequency of adverse events.
Future RCTs should address methodological limitations, including short follow-up periods and patient adherence.
Publisher
Sultan Qaboos University, College of Medicine and Health Sciences,Sultan Qaboos University,Sultan Qaboos University Medical Journal, College of Medicine & Health Sciences
Subject
